Neuphoria Therapeutics Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
1
- Stock Symbol
-
NEUP
- Investments
-
4
- Share Price
-
$2.49
- (As of Friday Closing)
Neuphoria Therapeutics General Information
Description
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Contact Information
Website
www.neuphoriatx.comCorporate Office
- 14 Millstone Road
- PBM 195
- Millis, MA 02054
- United States
Corporate Office
- 14 Millstone Road
- PBM 195
- Millis, MA 02054
- United States
Neuphoria Therapeutics Timeline
Neuphoria Therapeutics Stock Performance
As of 13-Nov-2026, Neuphoria Therapeutics’s stock price is $2.49. Its current market cap is $13.8M with 5.41M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.49 | $2.58 | $2.49 - $5.53 | $13.8M | 5.41M | 32.2K | -$3.06 |
Neuphoria Therapeutics Financials Summary
As of 30-Jun-2026, Neuphoria Therapeutics has a trailing 12-month revenue of $1.17M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 4,211 | 4,211 | (3,525) | 17,706,879 |
| Revenue | 1,174 | 1,174 | 15,649 | 0 |
| EBITDA | (13,594) | (13,594) | (342) | (15,137) |
| Net Income | (13,452) | (13,452) | (370) | (15,492) |
| Total Assets | 28,709 | 28,709 | 28,590 | 27,649 |
| Total Debt | 34 | 34 | 149 | 273 |
Neuphoria Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neuphoria Therapeutics Comparisons
Industry
Financing
Details
Neuphoria Therapeutics Competitors (36)
One of Neuphoria Therapeutics’s 36 competitors is Vistagen Therapeutics, a Corporation company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vistagen Therapeutics | Corporation | South San Francisco, CA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| BioXcel Therapeutics | Formerly VC-backed | New Haven, CT | ||||
| Praxis (Drug Discovery) | Formerly VC-backed | Boston, MA | ||||
| Climb Bio | Formerly VC-backed | Wellesley Hills, MA |
Neuphoria Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neuphoria Therapeutics Patents
Neuphoria Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024348342-A1 | Method of treating post-traumatic stress disorder | Pending | 28-Sep-2023 | ||
| EP-4784136-A1 | Method of treating post-traumatic stress disorder | Pending | 28-Sep-2023 | ||
| WO-2025068765-A1 | Method of treating post-traumatic stress disorder | Inactive | 28-Sep-2023 | ||
| AU-2023901981-A0 | Antibody-drug-conjugates and uses thereof for the treatment of cancer | Inactive | 23-Jun-2023 | ||
| AU-2023201463-A1 | Method of treating social anxiety disorder | Pending | 08-Mar-2023 | A61K31/5377 |
Neuphoria Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuphoria Therapeutics Acquisitions (4)
Neuphoria Therapeutics’s most recent deal was a Merger/Acquisition with Prestwick Chemical for . The deal was made on 23-Sep-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Prestwick Chemical | 23-Sep-2014 | Merger/Acquisition | Drug Discovery | ||
| Eclipse Therapeutics | 17-Sep-2012 | Merger/Acquisition | Pharmaceuticals | ||
| Iliad Chemicals | 24-May-2005 | Merger/Acquisition | Biotechnology | ||
| Neurofit (Drug Discovery) | 01-Jan-2005 | Merger/Acquisition | Drug Discovery |
Neuphoria Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
42.99 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Neuphoria Therapeutics Exits (2)
Neuphoria Therapeutics’s most recent exit was on 23-Sep-2014 from Prestwick Chemical. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Prestwick Chemical | 23-Sep-2014 | Completed |
|
||
| Neurofit (Drug Discovery) | 01-Jan-2005 | Merger/Acquisition | Completed |
Neuphoria Therapeutics FAQs
-
When was Neuphoria Therapeutics founded?
Neuphoria Therapeutics was founded in 1996.
-
Where is Neuphoria Therapeutics headquartered?
Neuphoria Therapeutics is headquartered in Millis, MA.
-
What is the size of Neuphoria Therapeutics?
Neuphoria Therapeutics has 1 total employees.
-
What industry is Neuphoria Therapeutics in?
Neuphoria Therapeutics’s primary industry is Drug Discovery.
-
Is Neuphoria Therapeutics a private or public company?
Neuphoria Therapeutics is a Public company.
-
What is Neuphoria Therapeutics’s stock symbol?
The ticker symbol for Neuphoria Therapeutics is NEUP.
-
What is the current stock price of Neuphoria Therapeutics?
As of 13-Nov-2026 the stock price of Neuphoria Therapeutics is $2.49.
-
What is the current market cap of Neuphoria Therapeutics?
The current market capitalization of Neuphoria Therapeutics is $13.8M.
-
What is Neuphoria Therapeutics’s current revenue?
The trailing twelve month revenue for Neuphoria Therapeutics is $1.17M.
-
Who are Neuphoria Therapeutics’s competitors?
Vistagen Therapeutics, Minerva Neurosciences, BioXcel Therapeutics, Praxis (Drug Discovery), and Climb Bio are some of the 36 competitors of Neuphoria Therapeutics.
-
What is Neuphoria Therapeutics’s annual earnings per share (EPS)?
Neuphoria Therapeutics’s EPS for 12 months was -$3.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
